Holen Sie sich die Stockscreener-App
803.17
2.49%
19.52
Schlusskurs vom Vortag:
$783.65
Offen:
$788.92
24-Stunden-Volumen:
974.10K
Relative Volume:
1.03
Marktkapitalisierung:
$84.91B
Einnahmen:
$14.34B
Nettoeinkommen (Verlust:
$4.50B
KGV:
19.32
EPS:
41.5626
Netto-Cashflow:
$3.77B
1W Leistung:
+2.25%
1M Leistung:
+5.83%
6M Leistung:
+43.03%
1J Leistung:
+19.12%
1-Tages-Spanne:
$785.00
$806.18
1-Wochen-Bereich:
$745.07
$806.18
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story - simplywall.st
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? - Insider Monkey
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating - marketscreener.com
Krilogy Financial LLC Invests $1.18 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illinois Municipal Retirement Fund Buys 2,599 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case - Bloomberg Law News
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial - TipRanks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? - TradingView
Rhumbline Advisers Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leuthold Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • Pfizer - openPR.com
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges - Finviz
Samsung Bioepis to launch ophthalmology biosimilar in U.S. next year - Yonhap News Agency
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $77,853.00 in Stock - MarketBeat
Insider Selling: Arthur Ryan Sells Shares of Regeneron Pharmaceu - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Sells $1,585,066.72 in Stock - MarketBeat
How to watch Regeneron's March healthcare investor talks - Stock Titan
Regeneron Announces Investor Conference Presentations - The Manila Times
Regeneron Pharmaceuticals Officer Sells Over $1.5 Million in Company Stock - TradingView
A Look At Regeneron (REGN) Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate - simplywall.st
Trading Systems Reacting to (REGN) Volatility - Stock Traders Daily
Skylands Capital LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ING Groep NV Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL - Yahoo Finance
Regeneron to present Phase 3 data on novel allergy antibodies at AAAAI - Investing.com South Africa
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Top Stock Reports for NVIDIA, Amazon & Regeneron - Nasdaq
Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says - marketscreener.com
Sanofi (SNY) Collaborates on New Allergy Treatment Insights - GuruFocus
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy - The Manila Times
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26 - Traders Union
Regeneron Rose 3% This Week. Here’s Where the Stock Could Be Headed in 2026 - TIKR.com
New antibody cocktails for cat and birch allergies show first Phase 3 data - Stock Titan
Should Regeneron’s (REGN) EYLEA HD Milestones and Buybacks Reshape Its Long-Term Investment Narrative? - simplywall.st
Envestnet Asset Management Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer & Co. Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Guggenheim Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Regeneron stock price target to $975 on Dupixent growth - Investing.com
Candriam S.C.A. Has $95.30 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bessemer Group Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
5.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):